Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer;Verfahrensanweisung zur radioiodtherapie und 131I- ganzkörperszintigraphie bei differenzierten schilddrüsenkarzinomen im kindes-und jugendalter

NuklearMedizin

Volumn 46, Issue 5, 2007, Pages 224-231

  Franzius, Christiane ^a,f   Dietlein, M ^b   Biermann, M ^d,e   Fruhwald M ^f   Linden, T ^f   Bucsky, P ^g   Reiners, C ^c   Schober, O ^a  

^a Kliniken und Polikliniken fur Nuklearmedizin   (Germany)

^b Kliniken und Polikliniken für Nuklearmedizin   (Germany)

^c Kliniken und Polikliniken für Nuklearmedizin   (Germany)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Adolescents; Children; Differentiated thyroid cancer; Paediatric patients; Procedure guidelines; Radioiodine therapy

Indexed keywords

ANTIEMETIC AGENT; IODINE 131; THYROID HORMONE; THYROTROPIN; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; PEDIATRICS; PRACTICE GUIDELINE; REVIEW; THYROID CANCER; WHOLE BODY SCINTISCANNING; ARTICLE; CHILD; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SPINAL CORD TUMOR; STANDARD; THYROID TUMOR; WHOLE BODY IMAGING;

CHILD; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; SPINAL NEOPLASMS; THYROID HORMONES; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 35348989316     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1160/nukmed-0288     Document Type: Review

References (44)

1. Alessandri A, KJ G, Blair G et al. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol 2000; 35: 41-46.
2. Biermann M, Schober O. Should high hTg levels in the absence of iodine uptake be treated. Eur J Nucl Med Mol Imaging 2003; 30: 160-163.
3. Casara D, Rubello D, Saladini G et al. Different features of pulmonary metastases in differenciated thyroid cancer: natural history and multivariate statistical analysis of prognostiv variables. J Nucl Med 1993; 34: 1626-1631.
4. Cooper D, Doherty G, Haugen B et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
5. Corrias A, Einaudi S, Chiorboli E et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab 2001; 86: 4644-4648.
6. Demidchik Y, Demidchik E, Reiners C et al. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 2006; 243: 525-532.
7. Deutsche Krebsgesellschaft. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Chirurgie. Informationszentrum für Standards in der Onkologie - ISTO. Maligne Schilddrüsentumore, 3. Auflage 2002 (www.uni-duesseldorf.de/AWMF).
8. Dietlein M, Dressler J, Eschner W et al. Verfahrensanweisung zur Radioiodtherapie (RIT) beim differenzierten Schilddrüsenkarzinom (Version 3). Nuklearmedizin 2007; 46: 213-219.
9. Dietlein M, Dressler J, Escher W et al. Verfahrensanweisung für die Iod-131-Ganzkörperszintigraphie beim differenzierten Schilddrü senkarzinom (Version 3). Nuklearmedizin 2007; 46: 206-212.
10. Dietlein M, Schober O, Schicha H. Über- oder Untertherapie des papillären Mikrokarzinoms der Schilddrüse? Überlegungen zur ablativen Radioiodtherapie. Nuklearmedizin 2004; 43: 107-114.
11. Dottorini M, Vignati A, Mazzucchelli L et al. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997; 38: 669-675.
12. Farahati J, Bucsky P, Parlowsky T et al. Characteristics of differentiated thyroid carcinoma in children and adolescents with respect to age, gender, and histology. Cancer 1997; 80: 2156-2162.
13. Farahati J, Demidchik E, Biko J et al. Inverse association between age and the time of radiation exposure and extent of disease in cases of radiation-induced childhood thyroid carcinoma in Belarus. Cancer 2000; 88: 1470-1476.
14. Farahati J, Reiners C, Demidchik E. Is the UICC/AJCC Classification of primary tumor in childhood thyroid carcinoma valid? J Nucl Med 1999; 40: 2125.
15. Fenton C, Lukes Y, Nicholson D et al. The ret/PTC Mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab 2000; 85: 1170-1175.
16. 123I. Eur J Nucl Med Mol Imaging 2002; 29: 783-788.
17. Hung W, Sarlis N. Current controversies in the managament of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002; 12: 683-702.
18. 131I therapy for thyroid cancer. Clinical Endocrinol 2002; 56: 755-758.
19. Iorcansky S, Herzovich V, Qualey R et al. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6553-6555.
20. Jarzab B, Handkiewicw-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocrine-Related Cancer 2005; 12: 773-803.
21. Jarzab B, Handkiewicw-Junak D, Wloch J et al. Multivariate analysis of prognostic factors for differentiated thyrois cancer in children. Eur J Nucl Med 2000; 27: 833-841.
22. Krassas G, Pontikides N. Male reproductive function in relation with thyroid alterations. Best Practice Res Clin Endocrinol Metab 2004; 18: 183-195.
23. Kuijt W, Huang S. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab 2006; 90: 6123-6125.
24. LaQuaglia M, Black T, Holcomb GI et al. Differentiated thyroid cancer: cilical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases, a report from the surgical discipline committee of the children's cancer group. J Pediatr Surg 2000; 35: 955-960.
25. Lassmann M, Biassoni L, Monieurs M et al. The New EANM Dosage Card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798.
26. Leboulleux S, Baudin E, Hartl D et al. Follicular-cell drived thyroid cancer in children. Eur J Cancer 2004; 40: 1655-1659.
27. Machans A, Holzhausen H, Dralle H. The prognostic value of primary size in papillary and folicular thyroid carcinoma. Cancer 2005; 103: 2269-2273.
28. Musholt T, Musholt P, Petrich T et al. Familiar papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment. World J Surg 2000; 24: 1409-1417.
29. Nakada K, Ishibashi T, Takei T et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46: 261-266.
30. Newman K, Black T, Heller G et al. Differentiated thyrois cancer: determination of disease progression in patients <21 years of age at diagnosis: a report from the surgical discipline committee of the children's cancer group. Ann Surg 1998; 227: 533-541.
31. Pacini F, Gasperi M, Fugazzola L et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35: 1418-1422.
32. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrin 2006; 154: 787-803.
33. Pacini F, Vorontsova T, Demidchik E et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occuring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1007; 82: 3563-3569.
34. Pelizzo M, Boschin I, Toniato A et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a onoinstitutional 12-year experience. Nucl Med Commun 2004; 25: 547-552.
35. Reiners C. Das kindliche Schilddrüsenkarzinom. In: Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms. Reiners C (ed). 2. Auflage ed. Bremen: Unimed 2006; 102-112.
36. Reiners C, Lassmann M, Hänscheid H. A perspective on post-Chernobyl radioablation in young females. J Nucl Med 2006; 47: 1563-1564.
37. Ringel M, Levine M. Current therapy for childhood thyroid cancer: optimal surgery and the legacy of king pyrrhus. Ann Surg Oncol 2003; 10: 4-6.
38. Robbins R, Tuttle R, Sharaf R et al. Preparation by recombinant human thyreotropin or horman withdrawel are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86: 619-625.
39. Samaan N, Schultz P, Hickey R et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992; 75: 714-720.
40. Samuel A, Rajashekharrao B, Shah D. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998; 39: 1531-1536.
41. Schlumberger M, De Vathaire F, Ceccarelli C et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not prelude pregnancy in thyroid cancer patients. J Nucl Med 1996; 37: 612-615.
42. Thompson G, Hay I. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg 2004; 28: 1187-1198.
43. van Tol K, Jager P, Piers D et al. Better yield of (18) fluorodeoxyglucose-positron emission tomography in patients with metastatic differenciated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002; 12: 381-387.
44. Wichers M, Benz E, Palmedo H et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000; 27: 503-507.